A women’s study found similar hair-score gains but less progression with oral minoxidil. Here’s what men should discuss with a clinician.
On October 29, 2026, the Journal of the American Academy of Dermatology published a retrospective comparison of low-dose oral minoxidil and 5% topical minoxidil foam for female pattern hair loss, according to Medscape.
Medscape’s report describes two related findings: similar average improvements in hair-loss scores and less recorded progression among women receiving oral treatment.
The score changes are points on the Sinclair scale. They are not percentages of new hair or counts of individual hairs. Turning those changes into a percentage of regrowth would misrepresent what the researchers measured.
The distinction between improvement and progression is the central story. Average improvement asks how much the group’s scores changed. Progression asks how often researchers recorded worsening. Those questions can produce different comparisons within the same study.
The authors described comparable rates of regrowth overall. They also suggested that oral treatment might offer an advantage for patients whose priority is preventing long-term progression. That is a more specific interpretation than saying the oral formulation delivered better results across the board.
For a reader following hair-treatment news, the useful habit is to keep the outcome attached to the claim. “Less recorded progression” accurately describes this finding. “More hair regrowth” does not accurately describe the average score comparison.
The limitations belong together before any practical interpretation. According to Medscape, this was a retrospective study from a single academic practice. It cannot establish that oral minoxidil caused the lower progression rate. Statistical adjustment does not turn that association into proof of a treatment effect.
The authors also reported that adherence data were unavailable and no washout period was specified. The groups had different average follow-up durations: 11.0 months for oral treatment and 15.8 months for topical treatment. That unequal observation time adds another complication to the progression comparison.
Finally, the participants were women with female pattern hair loss. These results cannot be transferred directly to male pattern hair loss or every other cause of thinning hair. They also do not guarantee how an individual will respond.
Together, those boundaries make this a useful comparative signal rather than a verdict on which formulation a man should choose. The appropriate next step is a better treatment conversation, not a personal treatment change based on the headline.
For a gay man weighing hair treatments, the practical value is greater clarity about the decision itself. Wanting fuller hair is a reasonable aesthetic goal. So is wanting to preserve what is already there. Neither goal needs to become a demand to look younger or match a particular version of male attractiveness.
The study gives those goals different names. It also gives you a way to ask more precise questions about expected benefits and medical trade-offs.
Start by separating those priorities in the conversation with a clinician. You might be interested in visible improvement. You might care more about limiting further thinning. Both may matter, but they are not interchangeable outcomes.
A useful question is: “When we discuss whether treatment is working, are we talking about regrowth or stabilization?” That keeps the discussion tied to an outcome rather than to the appeal of a particular formulation.
The same distinction applies when reading treatment coverage. A headline about preventing progression should not quietly become a promise of greater density. A group’s average improvement should not become a forecast for your own appearance.
For a broader view of the options, see GayFitLab’s guide to comparing hair-loss treatment approaches. Use that wider context to organize questions rather than treating any single comparison as the whole decision.
The oral route brings a safety discussion beyond what a photograph can show. A dermatologist quoted by Prevention notes that oral minoxidil is prescribed off-label for hair loss and can have systemic effects.
Those effects include dizziness and swelling, increased heart rate or palpitations, and unwanted facial or body hair. Prevention advises discussing individual risks with a clinician, particularly when cardiovascular conditions or low blood pressure are part of the medical history.
That changes the meaning of a treatment comparison. A possible benefit on one hair outcome is only part of the choice. The other part is whether that potential benefit fits the person’s health history and circumstances.
A focused discussion can cover:
These are conversation points, not a prescription or a substitute for assessment. Keep the emphasis on assessment before an aesthetic decision rather than treating a headline as an individualized recommendation.
The research supports discussing a change with a clinician. It does not support independently switching formulations or adjusting treatment to reproduce the oral group’s results.
The immediate adjustment is to the decision-making process rather than the treatment schedule. Bring the distinction between regrowth and progression into your next relevant appointment. Describe what you hope to achieve and the routine you currently follow.
If fitting treatment into daily life is part of the question, say so directly. That is useful context for a personal discussion. It should remain separate from the claim that one formulation produced less progression in this particular comparison.
Convenience and a measured hair outcome are different parts of a decision. A formulation that sounds simpler is not automatically the right choice for your health circumstances. Let the discussion include practicality without allowing practicality to stand in for a review of risks.
There is also no need to turn the choice into a test of how seriously you take your appearance. Choosing a pill is not a badge of commitment. Using a topical product is not evidence that you are settling for less. The relevant question is whether a plan fits your goals after its benefits and risks have been assessed.
For gay men over 35, that leaves room for appearance without making appearance the whole story. Hair can matter to confidence and personal style without becoming an obligation. An informed choice respects that interest while keeping the rest of your health in view.
Use these minoxidil findings to sharpen a clinician-led discussion about your hair goals and systemic risks, not as a reason to switch or adjust treatment yourself.
After weighing the minoxidil findings, the next step is placing hair-care choices within a fuller view of appearance and wellbeing, a subject GayFitLab covers for gay men 35+. Where generic men’s health coverage leaves gay context out, its research-led editorial addresses grooming and confidence without prescribing one preferred look or treating youthfulness as the goal.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
